Tirzepatide for Alcoholism
(TAP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
Who Is on the Research Team?
Heather Barkholtz, PhD
Principal Investigator
UW School of Pharmacy
Michael Chen, MD
Principal Investigator
UW School of Medicine and Public Health
Are You a Good Fit for This Trial?
This trial is for adults aged 21-55 who are taking the weight loss drug tirzepatide (Zepbound).Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tirzepatide and undergo various assessments including blood, breath, and urine sampling, cognitive assessments, and subjective evaluations
Follow-up
Participants are monitored for safety and effectiveness after treatment through follow-up correspondence
What Are the Treatments Tested in This Trial?
Interventions
- Acute Ethanol Dose
- Tirzepatide
Trial Overview
The study looks at how tirzepatide affects the way the body processes alcohol. Participants will receive a single dose of alcohol while on tirzepatide, and their body's response will be measured over about 4 weeks.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will complete a screening and enrollment visit, one study visit, and a follow-up correspondence over the course of approximately 4 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.